Pulmonary arterial hypertension (PAH) is a rare and progressive disease of the pulmonary arterial circulation that is characterized by a progressive rise in pulmonary vascular resistance, eventually leading to right-heart failure and death. There are currently 3 classes of drugs approved for the treatment of PAH: prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors. All of these therapies have been approved for use on the basis of relatively small, short-term studies, yet it is common for each to be administered (alone or in combination) over the lifetime of a patient with PAH. Very few prospective, well-controlled PAH studies have examined longterm clinical outcomes associated with current medical therapy. Therefore, data that support the long-term therapeutic benefits of these long-term PAH therapies are limited and derived primarily from uncontrolled, observational studies. In this perspective, the authors review the published research to assess the strengths and weaknesses of the data that support the long-term clinical benefit of current PAH therapies. The authors conclude that current medical therapies approved for the treatment of PAH can provide sustained benefits in hemodynamic function and exercise capacity. The cumulative evidence, in the form of meta-analysis and registry data, suggest that patients are living longer compared with untreated patients; the reasons are likely multifactorial. Although definitive evidence will require randomized and properly controlled long-term trials, the current evidence supports the long-term use of these drugs for the treatment of patients with PAH. (J Am Coll Cardiol 2011;57:1053-61) 
Pulmonary arterial hypertension (PAH) is a disease of the pulmonary circulation that is characterized by a progressive rise in pulmonary artery pressure and pulmonary vascular resistance, with limited dysfunction of the left ventricle (1) . PAH is a disease that often manifests with clinical symptoms such as shortness of breath and decreased functional capacity but eventually leads to right-heart failure and death (1) .
The pathogenesis of PAH is poorly understood, and the associated conditions that result in PAH are heterogenous and seemingly unrelated (2) ; however, it appears that all of these conditions ultimately lead to an insult to the pulmonary vasculature resulting in signaling imbalances between vasoconstrictive or proliferative (e.g., endothelin) and vasodilatory or antiproliferative (e.g., prostacyclin, nitric oxide) compounds. This imbalance is associated with the proliferation of endothelial and smooth muscle cells, as well as components of the extracellular matrix, resulting in the reduction and/or obliteration of luminal space in the pulmonary vasculature (3, 4) . Current PAH therapies have targeted these signaling pathways in an attempt to counteract these imbalances and delay or reverse the progressive obliteration of pulmonary microvasculature.
There are currently 3 classes of drugs approved for the treatment of PAH: prostacyclin analogues (e.g., epoprostenol, treprostinil, iloprost), endothelin receptor antagonists (e.g., ambrisentan, bosentan, sitaxsentan [sitaxsentan is only approved outside the U.S.*]), and phosphodiesterase type 5 inhibitors (e.g., sildenafil, tadalafil) (5, 6) . Considering the progressive and fatal nature of PAH, as well as the limited population of patients with this disease, nearly all of the current therapies were approved on the basis of relatively small (e.g., Ͻ500 patients) short-term studies of 12 to 24 weeks in duration (5) . Very few PAH studies have examined long-term clinical outcomes and efficacy measures using prospective, well-controlled designs. Therefore, data that support the durability of response and long-term therapeutic benefits of these longterm PAH therapies are limited and are derived primarily from uncontrolled, observational studies that are often reported using post hoc analyses, subgroup comparisons, and historical controls (Table 1) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) .
The purpose of this review is to evaluate the strengths and weaknesses of current PAH therapies. We accomplish this by critically reviewing the data from the published research that support the long-term clinical benefit of these therapies, excluding economic considerations. Data are presented descriptively, without the inclusion of statistical tests, with a focus on 3 key end points-exercise capacity, hemodynamic parameters, and survival-because these metrics were reported in the majority of PAH drug studies and were reported in a reasonably consistent manner.
Methods
Long-term clinical studies of patients with PAH that reported analyses of cardiopulmonary hemodynamic parameters, functional capacity (e.g., 6-min walking distance [6MWD]), and/or clinical outcomes (e.g., survival) published from January 1990 to March 2010 were identified using a computer-based search of the MEDLINE database. Studies were considered long-term if the treatment duration was approximately 1 year or greater. The studies identified ranged from case reports and small single-center trials to larger multicenter investigations that were often extensions of pivotal, short-term, randomized controlled trials. Because small, uncontrolled datasets are often inconclusive and highly variable, we chose to focus primarily on multicenter studies in adult patients with PAH and included only large, single-center reports (Ͼ50 patients). A few smaller studies were included, when they were considered to be key publications for specific drugs and larger studies were not available ( Table 1) .
This perspective review is not a meta-analysis or an analysis of the "raw data" from each trial. Statistical methods used in these studies varied widely, many were retrospective (often combining multiple studies or exploring specific subgroups in a post hoc manner), and without raw data, we could not assess the risk for improper reporting and missing data. Therefore, this clinical perspective presents the data descriptively, without the inclusion of statistical tests.
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Results
Description of long-term studies. The long-term PAH trials included in this review are summarized in Table 1 .
The analyses for these trials generally fall into 3 categories:
1) single-center retrospective studies; 2) multicenter, prospective extension studies of previous short-term controlled trials; and 3) post-hoc subgroup analyses that combined data from several long-term trials. All of these trials used open-label, observational designs. In fact, the only longterm, placebo-controlled PAH trial conducted to date was for the oral prostacyclin analogue beraprost (27) . In this 1-year study, improvements compared with placebo (and baseline) were observed for several clinical end points after 3 to 6 months of beraprost therapy, but these improvements were not maintained at later time points (e.g., 6MWD) ( Fig. 1 ). Despite an increase in 6MWD in this study at 12 weeks, there was no improvement in hemodynamic parameters, which may have been an important harbinger of a lack of efficacy with this beraprost formulation. Beraprost is not approved for the treatment of PAH in the U.S. or European Union, in part because of this lack of improvement, underscoring the risks of extrapolating results from short-term studies to long-term use. Therefore, although it remains the longest placebo-controlled PAH trial conducted to date, the results of this study are not included in the summary tables.
Most studies reported a mean study drug exposure time of 1 to 3 years, although a few of the earlier studies with calcium-channel blockers and epoprostenol followed patients for substantially longer periods (Table 1 ). Of note, most of the long-term studies only reported data for patients who continued to provide assessments at the later time points (Tables 2 and 3 ). Therefore, these "observed case" data likely represented biased, responder populations and must be interpreted with caution, because these data may be biased in favor of the therapy under study. Earlier clinical trials were limited to patients with primary pulmonary hypertension or idiopathic pulmonary arterial hypertension (IPAH) or with familial PAH or hereditary pulmonary hypertension, whereas later trials included associated etiologies of PAH (Table 4 ). This in turn led to varied physical status on enrollment, which is important, because it appears that PAH subgroups have different survival rates and responses to therapies (7, 8, 28) . Early studies, especially with epoprostenol, focused on patients with late-stage (New York Heart Association [NYHA] functional class III or IV) disease. This focus was appropriate at the time, considering the risks associated with this more invasive parenteral therapy. As the field evolved toward oral therapy, trials included larger proportions of patients with less severe disease, resulting in study populations with primarily mild to moderate PAH symptoms (NYHA functional class II or III). This is presumably related to the fact that patients suitable for oral therapies were more likely to be less sick. Differences in disease severity for the various study populations are important, as initial response to therapy and long-term treatment goals may differ for patients with earlier stage disease.
Long-Term Effects of Currently Approved PAH Therapies on Cardiopulmonary Hemodynamic Parameters
More recent trials also used different clinical end points than earlier studies with calcium-channel blockers, epoprostenol, and bosentan (Table 4 ). For these later trials, there has been less focus on hemodynamic parameters and survival and more focus on end points such as 6MWD and functional class. This may be due in part to the shift in study populations toward less severe baseline symptoms and also to the challenge of collecting invasive serial hemodynamic parameters in patients with PAH with less severe disease. There remains a need to find new "surrogate" markers of survival given the poor prognosis of the patients. Cardiopulmonary hemodynamic parameters. Hemodynamic assessments via right-heart catheterization provide a direct measure of disease progression relative to cardiopulmonary function. Unlike other routine assessments in PAH (e.g., functional class, quality of life, dyspnea), invasive hemodynamic parameters are relatively nonsubjective and provide a direct assessment of therapeutic response, even when measured in observational, open-label trials. Also, because PAH is a progressive disease that is defined by increased cardiopulmonary dysfunction (1), hemodynamic parameters are expected to progressively worsen relative to baseline in untreated patients (12, 29, 30) .
Several hemodynamic parameters have been shown to be prognostic for long-term outcomes (31) (32) (33) (34) (35) ; therefore, stabilization or improvement of cardiopulmonary hemodynamic parameters is a fundamental goal of medical therapy for PAH. As shown in Table 2 , modest hemodynamic improvements relative to baseline have been reported for several PAH therapies after uncontrolled long-term treatment. These improvements were most apparent for mean pulmonary artery pressure, pulmonary vascular resistance, Long-Term Effects of Currently Approved PAH Therapies on 6MWD and cardiac index, whereas decreases in mean right atrial pressure were relatively minimal or absent in many studies. Because patients with PAH hemodynamically deteriorate relative to baseline after some time point without treatment, it is generally assumed that these long-term improvements provide reasonable evidence of sustained hemodynamic benefit from calcium-channel blockers, prostacyclins, and endothelin receptor antagonists. However, nearly all of these studies reported long-term hemodynamic results for a subset of their original study populations, mostly those who had not died or progressed to other treatments (i.e., "responder populations"). These data also represent group averages, with some patients having large responses while other did not; it is important to note, however, that few patients had complete normalization of hemodynamic parameters or pulmonary vascular resistance. Nonetheless, the preponderance of the evidence strongly suggests that longterm hemodynamic function can be maintained at least in a subset of patients who respond favorably to treatment. Exercise capacity. Decreased exercise capacity, often with increased dyspnea, is a hallmark symptom of PAH (1) and an important prognostic indicator of survival in PAH (9, 10, 29, 36) . Although change in 6MWD has been extensively studied in short-term placebo-controlled trials, the long-term durability of improvement for this end point has been less rigorously reported. Nearly all short-term, placebo-controlled PAH trials have demonstrated that mean 6WMD is at or below baseline after approximately 12 to 24 weeks in untreated patients with PAH (11,12,30,37-40).
Here, the beraprost study (27) is informative, because 6MWD
for a PAH population with functional class II or III symptoms at baseline decreased by approximately 20 m after 12 months of placebo treatment (Fig. 1) . Thus, it reasonable that in a symptomatic placebo group, the mean 6MWD should be at or below baseline after a period of 1 year or more without therapy and that long-term increases in 6MWD in treated patients compared with baseline would provide reasonable evidence of sustained therapeutic benefit. However, although a sustained placebo effect over years is unlikely in patients with PAH, it cannot be disregarded entirely.
MISSING DATA COMPLICATE ANALYSES OF LONG-TERM
6MWD DATA. Interpretation of 6MWD data from longterm observational trials is challenging, because treatment effect estimates are heavily dependent on how data are analyzed relative to missing values that will inevitably accumulate over time. In short-term trials, this issue has been easier to address, typically with a worst-case penalty being applied to patients with missing data due to worsening clinical status or death (e.g., a 6MWD of 0 m is assigned for missing post-baseline assessments) (11, 12, 39) . This approach makes intuitive sense and has been reasonable for short-term trials for 2 reasons: 1) the short duration of these trials limited the amount of imputed data; and 2) the same penalty was applied to both the active and control groups, so therapeutic benefit could be assessed relative to an untreated population. For long-term, observational trials, neither of these criteria is met. With a fatal disease such as PAH, the amount of missing data increases with increased drug exposure; therefore, treatment effect estimates are depen- Table 1 . dent on the duration of exposure as well as therapeutic benefit. This in itself would not be problematic if there were an untreated control group that received the same penalty, as the measured response could be adjusted relative to a control group; however, this is not the case.
Summary of Study Populations and End Points of Long-Term Clinical Trials in PAH
An alternative but perhaps equally unsatisfying approach for the long-term assessment of 6MWD is to ignore missing data and analyze only those values observed at a specific time point (i.e., observed case or "responder population" analysis). As shown in Table 3 , this is the approach taken for nearly all long-term studies to date, many of which reported 6MWD data that excluded more than one-third of the entire study population (7, 9, (13) (14) (15) . This approach is inherently biased, as it enriches for a "responder population" that is most likely to show therapeutic benefit. Therefore, similar to the case for hemodynamic parameters, the most that can be concluded from these observed case analyses is that there appears to be sustained improvement in exercise capacity in a subpopulation of patients who remain on long-term therapy. The strength of these conclusions and the degree to which they can be generalized to patients in clinical practice depends on the proportion of the study population included in the analysis. Thus, we suggest that the reporting of long-term observed case data should always be accompanied with a detailed description of patients excluded from the analysis because of death, clinical worsening, adverse events, or other reasons.
Oudiz et al. (16) recently published a third approach for handling missing long-term data in PAH trials, which has not been previously done in other PAH trials. In this study, patients were treated with ambrisentan for up to 2 years and a last-observation-carried-forward method was used for the imputation of missing 6MWD data at later time points. The intent of this type of analysis is to capture worsening that occurs before the discontinuation of a patient and apply these values toward the final analysis. Although this approach allows data to be analyzed for all patients in a study, it is not without limitations. Actual 6MWD results at a specific time point after discontinuation (if collected) might have been worse than the imputed last-observation-carriedforward value, especially if the patient was left untreated. Furthermore, this approach would not include penalties for patients with missing data who experience an acute worsening event (e.g., death) without previous decline. Nonetheless, the treatment effect estimates using this lastobservation-carried-forward approach ( Table 3) were more conservative (i.e., 2-to 3-fold lower in several groups) than an observed case analysis from the same study (Fig. 2) .
INTERPRETATION OF BENEFIT ON THE BASIS OF CURRENT
LONG-TERM 6MWD DATA. Considering the different analyses and presentations summarized in Table 3 , these longterm 6MWD data should not be compared. Nor should the 6MWD values presented for individual studies be overemphasized, because they are estimates that are inherently linked to the analysis methods used to generate them. Yet considering the progressive nature of PAH and the known behavior of placebo groups in short-term trials for this end point, the clinically relevant increases in 6MWD reported in these long-term studies suggest that current therapies are capable of providing sustained improvements in exercise capacity in patients with PAH. Survival. Few randomized, well-controlled PAH trials have demonstrated a survival advantage for current medical therapy (38, 41) . This may be due in part to the relatively small sample sizes and short durations of follow-up in these trials, resulting in low statistical power to detect these events. To overcome these statistical limitations, Galie et al. (42) recently conducted a meta-analysis of more than 20 randomized, controlled short-term PAH trials (mean duration 14.3 weeks), and from these pooled data, they concluded that current PAH therapies were associated with a 43% reduction in mortality (relative risk: 0.57; 95% confidence interval: 0.35 to 0.92). Although these results are encouraging, it is unclear if they support a true long-term survival advantage for medical therapy or if the risk reduction observed in this analysis was due to a relatively modest delay in mortality beyond the short-term observation periods of these studies. Thus, the effects of medical therapy on survival must still be inferred primarily from long-term observational studies and historical controls.
During the 1980s, a national registry was established to study the natural history of patients with primary pulmonary hypertension (i.e., IPAH or heritable PAH) receiving no PAH-specific therapy (43) . From this registry, a median survival of 2.8 years was reported in the overall population, with 1-, 3-, and 5-year survival rates of 68%, 48%, and 34%, respectively (31) . Approximately two-thirds of patients in this registry were considered in NYHA functional class III or IV at baseline, and these patients had considerably lower median survival times (2.6 and 0.5 years for NYHA functional classes III and IV, respectively) compared with patients with baseline class I or II symptoms (4.9 years). Since that time, several reports have indicated that baseline functional class, as well as exercise capacity and hemodynamic parameters, are important predictors of long-term survival (9,10,17,44 -46) . From the National Institutes of Health (NIH) registry dataset, a formula was developed to predict the risk for death for IPAH or heritable PAH and patients with anorexigen-associated PAH on the basis of 3 baseline hemodynamic parameters (mean pulmonary artery pressure, mean right atrial pressure, and cardiac index) (31) . As shown in Table 5 , many long-term studies have compared predicted survival on the basis of this formula to observed survival in various IPAH populations, and in nearly every report, the comparison has favored medical therapy. Again, the data are encouraging and consistent with the long-term data reported for cardiopulmonary hemodynamic parameters and exercise capacity; yet, they do not constitute definitive proof of a survival benefit. In fact, recent data from several contemporary PAH registry studies have suggested that survival estimates as predicted by the NIH formula may no longer be relevant and/or accurate in the current era of PAH-directed therapy. The Pulmonary Hypertension Connection registry evaluated the long-term survival of 576 patients with PAH from 3 expert centers in Chicago who received various PAH treatments from 1991 to 2007 (47) . In the overall PAH cohort, observed survival was 86%, 69%, and 61% at 1, 3, and 5 years, respectively. In 247 patients with idiopathic, familial, and anorexigen-associated PAH (i.e., etiologies similar to those in the NIH model), observed survival was significantly higher than NIH-predicted survival at 1 year (92% vs. 65%), 3 years (75% vs. 43%), and 5 years (66% vs. 32%), respectively. A second, independent registry of 354 adults in France with idiopathic, familial, or anorexigenassociated PAH who received various PAH treatments over a period from 2002 to 2003 also observed similar 1-, 3-, and 5-year survival rates (83%, 67%, and 58%, respectively), and these observed survival rates were approximately 10 percentage points higher than those predicted by the NIH formula (46) . Finally, recent analyses from a U.S.-based, multicenter Long-Term Effects of Currently Approved PAH Therapies on Survival registry that was initiated in 2006 to examine long-term outcomes of patients with PAH treated with various PAHspecific drugs (the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management) demonstrated that the NIH formula has relatively low power (i.e., slightly better than random chance) to discriminate between patients at high and low risk for death at 1 year (45) . The poor performance of the NIH formula when applied to contemporary PAH populations likely reflects important differences in the diagnosis and treatment of PAH between the early 1980s and the current era. Although none of the recent registry studies specifically examined response to therapy as a predictor of survival, several did develop new predictive models (44, 45) that include multiple risk factors known to be modified by current medical therapy (e.g., 6MWD, B-type natriuretic peptide, hemodynamic parameters, functional class). Therefore, medical therapy should have a positive impact on survival in patients whose response to therapy places them in a better risk category for these models. Prospective, long-term studies will be required to test these hypotheses and the impact of specific medical therapies on survival.
Conclusions
Published data indicate that the current medical therapy approved for the treatment of PAH can provide sustained benefits on hemodynamic function and exercise capacity, 2 clinical measures that help predict survival in patients with PAH. Consistent with these data, a meta-analysis of shortterm randomized trials suggests that current medical therapies decrease the risk for death in patients with PAH. In long-term observational studies, patients with PAH receiving medical therapy have better survival rates than predicted outcomes on the basis of untreated historical controls. However, it is unknown whether long-term response to current medical therapy will be similar in patients with pulmonary hypertension due to other etiologies not previously enrolled in clinical studies. Furthermore, nearly all of these long-term studies allowed for the addition of other approved PAH therapies; therefore, survival rates observed in these long-term extension trials are not due solely to the original therapies tested in the initial short-term placebocontrolled trials.
The present data are consistent with the conclusion that current medical therapies provide sustained clinical benefits in patients with PAH, yet definitive evidence will require randomized and properly controlled long-term trials, preferably with composite clinical outcome end points and/or goal-oriented designs. Several such studies have recently been completed or are currently under way that will compare long-term treatment strategies such as first-line monotherapy, add-on combination therapy (e.g., Pulmonary Arterial Hypertension Combination Study of Epoprostenol and Sildenafil, Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension), and, more important, first-line combinations therapy (e.g., A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension) (48 -50) . These studies should substantially deepen our understanding of the long-term benefits of medical therapy in this devastating disease. In the meantime, the current evidence supports the long-term use of these drugs for the treatment of PAH while the search for a curative therapeutic regimen continues.
